Global Postmenopausal Vaginal Atrophy Drugs Sales Market Report 2021

1 Postmenopausal Vaginal Atrophy Drugs Market Overview

• 1.1 Postmenopausal Vaginal Atrophy Drugs Product Scope
• 1.2 Postmenopausal Vaginal Atrophy Drugs Segment by Type
  • 1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2016 & 2021 & 2027)
  • 1.2.2 Premarin
  • 1.2.3 Vagifem
  • 1.2.4 Estrace
  • 1.2.5 Estring
  • 1.2.6 Femring
• 1.3 Postmenopausal Vaginal Atrophy Drugs Segment by Application
  • 1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Comparison by Application (2016 & 2021 & 2027)
  • 1.3.2 Vaginal Gels
  • 1.3.3 Creams
  • 1.3.4 Tablets
  • 1.3.5 Rings
  • 1.3.6 Patches
• 1.4 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts (2016-2027)
  • 1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size in Value Growth Rate (2016-2027)
  • 1.4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size in Volume Growth Rate (2016-2027)
  • 1.4.3 Global Postmenopausal Vaginal Atrophy Drugs Price Trends (2016-2027)

2 Postmenopausal Vaginal Atrophy Drugs Estimates and Forecasts by Region

• 2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2016 VS 2021 VS 2027
• 2.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario by Region (2016-2021)
  • 2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2016-2021)
  • 2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2016-2021)
• 2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts by Region (2022-2027)
  • 2.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Estimates and Forecasts by Region (2022-2027)
  • 2.3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Region (2022-2027)
• 2.4 Geographic Market Analysis: Market Facts & Figures
  • 2.4.1 North America Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2016-2027)
  • 2.4.2 Europe Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2016-2027)
  • 2.4.3 China Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2016-2027)
  • 2.4.4 Japan Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2016-2027)
  • 2.4.5 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2016-2027)
  • 2.4.6 India Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2016-2027)

3 Global Postmenopausal Vaginal Atrophy Drugs Competition Landscape by Players

• 3.1 Global Top Postmenopausal Vaginal Atrophy Drugs Players by Sales (2016-2021)
• 3.2 Global Top Postmenopausal Vaginal Atrophy Drugs Players by Revenue (2016-2021)
• 3.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2020)
• 3.4 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Company (2016-2021)
• 3.5 Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Sites, Area Served, Product Type
• 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type

• 4.1 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Review by Type (2016-2021)
  • 4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2016-2021)
  • 4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2016-2021)
  • 4.1.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2016-2021)
• 4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts by Type (2022-2027)
  • 4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2022-2027)
  • 4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2022-2027)
  • 4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Type (2022-2027)

5 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application

• 5.1 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Review by Application (2016-2021)
  • 5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2016-2021)
  • 5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2016-2021)
  • 5.1.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2016-2021)
• 5.2 Global Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts by Application (2022-2027)
  • 5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2022-2027)
  • 5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2022-2027)
  • 5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2022-2027)

6 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures

• 6.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Company
  • 6.1.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Company (2016-2021)
  • 6.1.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2016-2021)
• 6.2 North America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type
  • 6.2.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2016-2021)
  • 6.2.2 North America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2022-2027)
• 6.3 North America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application
  • 6.3.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2016-2021)
  • 6.3.2 North America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2022-2027)

7 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures

• 7.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Company
  • 7.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Company (2016-2021)
  • 7.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2016-2021)
• 7.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type
  • 7.2.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2016-2021)
  • 7.2.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2022-2027)
• 7.3 Europe Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application
  • 7.3.1 Europe 138 Sales Breakdown by Application (2016-2021)
  • 7.3.2 Europe 138 Sales Breakdown by Application (2022-2027)

8 China Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures

• 8.1 China Postmenopausal Vaginal Atrophy Drugs Sales by Company
  • 8.1.1 China Postmenopausal Vaginal Atrophy Drugs Sales by Company (2016-2021)
  • 8.1.2 China Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2016-2021)
• 8.2 China Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type
  • 8.2.1 China Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2016-2021)
  • 8.2.2 China Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2022-2027)
• 8.3 China Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application
  • 8.3.1 China 243 Sales Breakdown by Application (2016-2021)
  • 8.3.2 China 243 Sales Breakdown by Application (2022-2027)

9 Japan Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures

• 9.1 Japan Postmenopausal Vaginal Atrophy Drugs Sales by Company
  • 9.1.1 Japan Postmenopausal Vaginal Atrophy Drugs Sales by Company (2016-2021)
  • 9.1.2 Japan Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2016-2021)
• 9.2 Japan Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type
  • 9.2.1 Japan Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2016-2021)
  • 9.2.2 Japan Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2022-2027)
• 9.3 Japan Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application
  • 9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
  • 9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures

• 10.1 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales by Company
  • 10.1.1 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales by Company (2016-2021)
  • 10.1.2 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2016-2021)
• 10.2 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type
  • 10.2.1 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2016-2021)
  • 10.2.2 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2022-2027)
• 10.3 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application
  • 10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
  • 10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)

11 India Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures

• 11.1 India Postmenopausal Vaginal Atrophy Drugs Sales by Company
  • 11.1.1 India Postmenopausal Vaginal Atrophy Drugs Sales by Company (2016-2021)
  • 11.1.2 India Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2016-2021)
• 11.2 India Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type
  • 11.2.1 India Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2016-2021)
  • 11.2.2 India Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2022-2027)
• 11.3 India Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application
  • 11.3.1 India Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2016-2021)
  • 11.3.2 India Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Postmenopausal Vaginal Atrophy Drugs Business

• 12.1 Actavis plc
  • 12.1.1 Actavis plc Corporation Information
  • 12.1.2 Actavis plc Business Overview
  • 12.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
  • 12.1.5 Actavis plc Recent Development
• 12.2 Bionovo, Inc.
  • 12.2.1 Bionovo, Inc. Corporation Information
  • 12.2.2 Bionovo, Inc. Business Overview
  • 12.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
  • 12.2.5 Bionovo, Inc. Recent Development
• 12.3 Endoceutics, Inc.
  • 12.3.1 Endoceutics, Inc. Corporation Information
  • 12.3.2 Endoceutics, Inc. Business Overview
  • 12.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
  • 12.3.5 Endoceutics, Inc. Recent Development
• 12.4 Novo Nordisk A/S
  • 12.4.1 Novo Nordisk A/S Corporation Information
  • 12.4.2 Novo Nordisk A/S Business Overview
  • 12.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
  • 12.4.5 Novo Nordisk A/S Recent Development
• 12.5 Pfizer Inc.
  • 12.5.1 Pfizer Inc. Corporation Information
  • 12.5.2 Pfizer Inc. Business Overview
  • 12.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
  • 12.5.5 Pfizer Inc. Recent Development
• 12.6 Teva Pharmaceuticals Ltd.
  • 12.6.1 Teva Pharmaceuticals Ltd. Corporation Information
  • 12.6.2 Teva Pharmaceuticals Ltd. Business Overview
  • 12.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
  • 12.6.5 Teva Pharmaceuticals Ltd. Recent Development
• 12.7 Therapeutics MD, Inc.
  • 12.7.1 Therapeutics MD, Inc. Corporation Information
  • 12.7.2 Therapeutics MD, Inc. Business Overview
  • 12.7.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
  • 12.7.5 Therapeutics MD, Inc. Recent Development
• 12.8 Shionogi & Company
  • 12.8.1 Shionogi & Company Corporation Information
  • 12.8.2 Shionogi & Company Business Overview
  • 12.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
  • 12.8.5 Shionogi & Company Recent Development
• 12.9 Allergan plc
  • 12.9.1 Allergan plc Corporation Information
  • 12.9.2 Allergan plc Business Overview
  • 12.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
  • 12.9.5 Allergan plc Recent Development
• 12.10 Shionogi & Co. Ltd.
  • 12.10.1 Shionogi & Co. Ltd. Corporation Information
  • 12.10.2 Shionogi & Co. Ltd. Business Overview
  • 12.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
  • 12.10.5 Shionogi & Co. Ltd. Recent Development

13 Postmenopausal Vaginal Atrophy Drugs Manufacturing Cost Analysis

• 13.1 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials Analysis
  • 13.1.1 Key Raw Materials
  • 13.1.2 Key Raw Materials Price Trend
  • 13.1.3 Key Suppliers of Raw Materials
• 13.2 Proportion of Manufacturing Cost Structure
• 13.3 Manufacturing Process Analysis of Postmenopausal Vaginal Atrophy Drugs
• 13.4 Postmenopausal Vaginal Atrophy Drugs Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers

• 14.1 Marketing Channel
• 14.2 Postmenopausal Vaginal Atrophy Drugs Distributors List
• 14.3 Postmenopausal Vaginal Atrophy Drugs Customers

15 Market Dynamics

• 15.1 Postmenopausal Vaginal Atrophy Drugs Market Trends
• 15.2 Postmenopausal Vaginal Atrophy Drugs Drivers
• 15.3 Postmenopausal Vaginal Atrophy Drugs Market Challenges
• 15.4 Postmenopausal Vaginal Atrophy Drugs Market Restraints

16 Research Findings and Conclusion

17 Appendix

• 17.1 Research Methodology
  • 17.1.1 Methodology/Research Approach
  • 17.1.2 Data Source
• 17.2 Author List